Sanofi and GSK recently signed agreements with the United States for up to 100mln doses of the vaccine and to supply the UK with 60mln doses.
The doses for the EU would be manufactured in European countries including France, Belgium, Germany and Italy, the drugs group’s said in a joint statement.
“Today’s announcement helps to ensure that millions of Europeans will have access to a potential vaccine protecting against COVID-19, once proven safe and effective,” said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.
“It has been our steadfast commitment to provide a vaccine that is affordable and accessible to everyone, and we are grateful to the European Commission for their ongoing engagement and shared support of this effort,” he added.
Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020.
If data is positive, regulatory approval could be achieved by the first half of 2021, said the French company.
In parallel, Sanofi and GSK said they are scaling up manufacturing of the antigen (Sanofi) and adjuvant (Glaxo) to produce up to 1bn doses per year overall.
Published at Mon, 03 Aug 2020 07:36:00 +0000-GlaxoSmithKline and Sanofi to supply EU with 300mln COVID-19 vaccine doses